Wednesday, July 8, 2026

pharma · Rectal Cancer · Fanconi Anemia · RCKT

Rocket Pharmaceuticals

Rocket Pharmaceuticals is a pharma organization headquartered in Cranbury, USA. It trades on NYSE under ticker RCKT. Primary therapeutic focus areas include Rectal Cancer, Fanconi Anemia, Danon Disease, PKP2 Arrhythmogen

9 Cedarbrook Dr, Cranbury, New Jersey 08512, US HQ
2015 Founded
226 Employees
Public company Type
RCKT · NYSE Ticker
Company details
Status
Public
HQ
9 Cedarbrook Dr, Cranbury, New Jersey 08512, US
Founded
2015
Employees
226
Programs
11
Drugs
10
Patents
1
Clinical program

RP-A501

Phase 2 · gene therapy · Danon Disease

RP-A501 for Danon Disease is a Phase 2 program (gene_therapy) at Rocket Pharmaceuticals B.V. with 2 ClinicalTrials.gov record(s).

Internal code RP-A501-0123

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Rocket Pharmaceuticals B.V.
Phase
Phase 2
Modality
gene_therapy
Indication
Danon Disease
Status
active
Trials
2

Clinical trials